XML 47 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Schedule of Financial Data for Business Segments
The financial data for the two business segments are as follows ($ amounts in thousands):

 
Three months ended
 
March 31, 2014
 
March 31, 2013
Revenues:
 
 
 
Par Pharmaceutical
$
273,806

 
$
272,800

Strativa
15,278

 
17,396

Total revenues
$
289,084

 
$
290,196

 
 
 
 
Gross margin:
 
 
 
Par Pharmaceutical
$
83,644

 
$
59,685

Strativa
10,670

 
11,759

Total gross margin
$
94,314

 
$
71,444

 
 
 
 
Operating (loss) income:
 
 
 
Par Pharmaceutical
$
(23,260
)
 
$
9,523

Strativa
(10,895
)
 
(914
)
Total operating (loss) income
$
(34,155
)
 
$
8,609

Interest income
14

 
37

Interest expense
(25,467
)
 
(24,036
)
Loss on debt extinguishment
(3,989
)
 
(7,335
)
Benefit for income taxes
(24,232
)
 
(7,979
)
Net loss
$
(39,365
)
 
$
(14,746
)
Schedule of Total Revenues of Top Selling Products
Total revenues of our top selling products were as follows ($ amounts in thousands):

 
Three months ended
 
March 31, 2014
 
March 31, 2013
Product
 
 
 
Par Pharmaceutical
 
 
 
Budesonide (Entocort® EC)
$
37,349

 
$
50,403

Propafenone (Rythmol SR®)
21,112

 
17,159

Divalproex (Depakote®)
20,405

 
1,426

Bupropion ER (Wellbutrin)
16,342

 
8,253

Metoprolol succinate ER (Toprol-XL®)
14,117

 
19,401

Other (1)
145,631

 
98,402

Other product related revenues (2)
5,439

 
6,779

Total Par Pharmaceutical Revenues
$
273,806

 
$
272,800

 
 
 
 
Strativa
 
 
 
Megace® ES
$
8,154

 
$
10,536

Nascobal® Nasal Spray
6,324

 
6,202

Other
(12
)
 
(241
)
Other product related revenues (2)
812

 
899

Total Strativa Revenues
$
15,278

 
$
17,396


(1)
The further detailing of revenues of the other approximately 80 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the three-month periods ended March 31, 2014 and 2013.
(2)
Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.